Pharma Pulse: GSK Invests $30B in US Manufacturing, GLP-1s Show Heart Benefits, and Roche Buys 89bio for Metabolic Pipeline

This episode of Pharma Pulse covers GSK’s $30 billion plan to expand US biopharma production, new evidence that weekly GLP-1 therapies significantly reduce cardiovascular risks, and Roche’s acquisition of 89bio to add the FGF21 analog Pegozafermin to its growing metabolic disease portfolio.